Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.05
BSX's Cash to Debt is ranked lower than
60% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 6.28 vs. BSX: 0.05 )
BSX' s 10-Year Cash to Debt Range
Min: 0.03   Max: 2.09
Current: 0.05

0.03
2.09
Equity to Asset 0.40
BSX's Equity to Asset is ranked lower than
53% of the 358 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. BSX: 0.40 )
BSX' s 10-Year Equity to Asset Range
Min: 0.21   Max: 0.79
Current: 0.4

0.21
0.79
Interest Coverage 0.37
BSX's Interest Coverage is ranked lower than
63% of the 222 Companies
in the Global Medical Devices industry.

( Industry Median: 205.72 vs. BSX: 0.37 )
BSX' s 10-Year Interest Coverage Range
Min: 0.37   Max: 65
Current: 0.37

0.37
65
F-Score: 6
Z-Score: 0.76
M-Score: -2.79
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 1.68
BSX's Operating margin (%) is ranked higher than
64% of the 363 Companies
in the Global Medical Devices industry.

( Industry Median: 6.75 vs. BSX: 1.68 )
BSX' s 10-Year Operating margin (%) Range
Min: -53.36   Max: 28.95
Current: 1.68

-53.36
28.95
Net-margin (%) -1.69
BSX's Net-margin (%) is ranked higher than
59% of the 363 Companies
in the Global Medical Devices industry.

( Industry Median: 5.06 vs. BSX: -1.69 )
BSX' s 10-Year Net-margin (%) Range
Min: -56.12   Max: 18.88
Current: -1.69

-56.12
18.88
ROE (%) -1.85
BSX's ROE (%) is ranked higher than
59% of the 363 Companies
in the Global Medical Devices industry.

( Industry Median: 5.79 vs. BSX: -1.85 )
BSX' s 10-Year ROE (%) Range
Min: -59.21   Max: 26.39
Current: -1.85

-59.21
26.39
ROA (%) -0.73
BSX's ROA (%) is ranked higher than
61% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 3.38 vs. BSX: -0.73 )
BSX' s 10-Year ROA (%) Range
Min: -23.71   Max: 18.52
Current: -0.73

-23.71
18.52
ROC (Joel Greenblatt) (%) 4.76
BSX's ROC (Joel Greenblatt) (%) is ranked higher than
65% of the 376 Companies
in the Global Medical Devices industry.

( Industry Median: 12.75 vs. BSX: 4.76 )
BSX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -148.14   Max: 137.83
Current: 4.76

-148.14
137.83
Revenue Growth (%) 1.20
BSX's Revenue Growth (%) is ranked higher than
63% of the 278 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. BSX: 1.20 )
BSX' s 10-Year Revenue Growth (%) Range
Min: -10.5   Max: 28.9
Current: 1.2

-10.5
28.9
EBITDA Growth (%) 80.70
BSX's EBITDA Growth (%) is ranked higher than
98% of the 249 Companies
in the Global Medical Devices industry.

( Industry Median: -3.70 vs. BSX: 80.70 )
BSX' s 10-Year EBITDA Growth (%) Range
Min: -72   Max: 283.2
Current: 80.7

-72
283.2
EPS Growth (%) -49.50
BSX's EPS Growth (%) is ranked lower than
52% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: -2.80 vs. BSX: -49.50 )
BSX' s 10-Year EPS Growth (%) Range
Min: -49.5   Max: 124.6
Current: -49.5

-49.5
124.6
» BSX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

BSX Guru Trades in Q1 2013

Tom Russo 209 sh (New)
Jim Simons 8,400,805 sh (+248.83%)
Mario Gabelli 2,768,005 sh (+14.46%)
Leon Cooperman 16,473,300 sh (+13.43%)
Michael Price 1,700,000 sh (unchged)
Ray Dalio Sold Out
Pioneer Investments Sold Out
Dodge & Cox 95,996,823 sh (-1.58%)
Vanguard Health Care Fund 45,385,200 sh (-2.61%)
Diamond Hill Capital 17,198,821 sh (-2.68%)
PRIMECAP Management 49,253,619 sh (-4.01%)
Charles Brandes 16,909,816 sh (-10.46%)
Joel Greenblatt 124,980 sh (-20.11%)
Paul Tudor Jones 13,700 sh (-83.09%)
Steven Cohen 154,075 sh (-94.69%)
» More
Q2 2013

BSX Guru Trades in Q2 2013

Pioneer Investments 14,623 sh (New)
Stanley Druckenmiller 1,000,000 sh (New)
Jim Simons 10,339,305 sh (+23.08%)
Diamond Hill Capital 20,465,802 sh (+19%)
Michael Price 1,700,000 sh (unchged)
Vanguard Health Care Fund 45,385,200 sh (unchged)
Tom Russo Sold Out
Paul Tudor Jones Sold Out
Leon Cooperman 16,462,100 sh (-0.07%)
PRIMECAP Management 49,039,219 sh (-0.44%)
Mario Gabelli 2,539,505 sh (-8.26%)
Dodge & Cox 81,801,130 sh (-14.79%)
Joel Greenblatt 60,894 sh (-51.28%)
Steven Cohen 71,027 sh (-53.9%)
Charles Brandes 624,088 sh (-96.31%)
» More
Q3 2013

BSX Guru Trades in Q3 2013

Paul Tudor Jones 13,100 sh (New)
Steven Cohen 293,313 sh (+312.96%)
Diamond Hill Capital 20,669,649 sh (+1%)
Michael Price 1,700,000 sh (unchged)
Charles Brandes Sold Out
Pioneer Investments Sold Out
Stanley Druckenmiller Sold Out
PRIMECAP Management 48,662,519 sh (-0.77%)
Mario Gabelli 2,234,905 sh (-11.99%)
Vanguard Health Care Fund 38,240,700 sh (-15.74%)
Leon Cooperman 13,467,416 sh (-18.19%)
Dodge & Cox 59,157,107 sh (-27.68%)
Jim Simons 4,803,505 sh (-53.54%)
Joel Greenblatt 18,744 sh (-69.22%)
» More
Q4 2013

BSX Guru Trades in Q4 2013

Ray Dalio 123,584 sh (New)
Jeremy Grantham 78,020 sh (New)
Steven Cohen 2,984,052 sh (+917.36%)
Michael Price 2,000,000 sh (+17.65%)
Diamond Hill Capital 21,034,396 sh (+1.76%)
Steven Cohen 1,657,400 sh (unchged)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
PRIMECAP Management 48,405,219 sh (-0.53%)
Mario Gabelli 2,201,305 sh (-1.5%)
Vanguard Health Care Fund 36,787,000 sh (-3.8%)
Jim Simons 4,358,620 sh (-9.26%)
Dodge & Cox 45,938,468 sh (-22.34%)
Leon Cooperman 8,533,099 sh (-36.64%)
» More
» Details

Insider Trades

Latest Guru Trades with BSX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Leon Cooperman 2013-12-31 Reduce -36.64%0.88%$11.18 - $12.38 $ 13.6516%8533099
Michael Price 2013-12-31 Add 17.65%0.47%$11.18 - $12.38 $ 13.6516%2000000
Dodge & Cox 2013-12-31 Reduce -22.34%0.18%$11.18 - $12.38 $ 13.6516%45938468
Ray Dalio 2013-12-31 New Buy0.01%$11.18 - $12.38 $ 13.6516%123584
Joel Greenblatt 2013-12-31 Sold Out 0.01%$11.18 - $12.38 $ 13.6516%0
Leon Cooperman 2013-09-30 Reduce -18.19%0.42%$9.15 - $11.99 $ 13.6526%13467416
Dodge & Cox 2013-09-30 Reduce -27.68%0.25%$9.15 - $11.99 $ 13.6526%59157107
Vanguard Health Care Fund 2013-09-30 Reduce -15.74%0.24%$9.15 - $11.99 $ 13.6526%38240700
Charles Brandes 2013-09-30 Sold Out 0.07%$9.15 - $11.99 $ 13.6526%0
Joel Greenblatt 2013-09-30 Reduce -69.22%0.02%$9.15 - $11.99 $ 13.6526%18744
Charles Brandes 2013-06-30 Reduce -96.31%1.54%$7.09 - $9.64 $ 13.6561%624088
Dodge & Cox 2013-06-30 Reduce -14.79%0.14%$7.09 - $9.64 $ 13.6561%81801130
Joel Greenblatt 2013-06-30 Reduce -51.28%0.03%$7.09 - $9.64 $ 13.6561%60894
Leon Cooperman 2013-03-31 Add 13.43%0.24%$5.73 - $7.81 $ 13.6592%16473300
Joel Greenblatt 2013-03-31 Reduce -20.11%0.01%$5.73 - $7.81 $ 13.6592%124980
Ray Dalio 2013-03-31 Sold Out 0.0025%$5.73 - $7.81 $ 13.6592%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Boston Scientific Corporation

Diamond Hill Capital Comments on Boston Scientific Corp - Jan 15, 2014

Boston Scientific Corp. (BSX), a medical device manufacturer, recently reported its first quarter of growth in more than three years, while also raising its earnings outlook. An emerging pipeline of new products offers the potential for continued improvement and the potential to return to mid-single digit revenue growth.

From Diamond Hill Capital (Trades, Portfolio) Large Cap Fund third quarter 2013 commentary.

Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about Boston Scientific Corporation

Diamond Hill Capital Comments on Boston Scientific Corp
Boston Scientific Corp. (BSX), a medical device manufacturer, recently reported its first quarter of growth in more than three years, while also raising its earnings outlook. An emerging pipeline of new products offers the potential for continued improvement and the potential to return to mid-single digit revenue growth. Read more...
BSX and ABMD Highlight Increased Insider Buying in the Medical Technology Sector
In the past week we saw an increase in insider buying coming from the health care industry. Last week GuruFocus reported 31 different insider buys coming from 19 different health care-based companies. These buys spanned across the sector from research and development labs to pharmaceutical companies. The following four companies are all a part of the medical supply sector of the health care industry. They represent significant insider buys coming from one or more directors or corporate executives. Read more...

Ratios

vs
industry
vs
history
P/B 2.79
BSX's P/B is ranked higher than
62% of the 355 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. BSX: 2.79 )
BSX' s 10-Year P/B Range
Min: 0.59   Max: 12.21
Current: 2.79

0.59
12.21
P/S 2.58
BSX's P/S is ranked higher than
56% of the 378 Companies
in the Global Medical Devices industry.

( Industry Median: 2.80 vs. BSX: 2.58 )
BSX' s 10-Year P/S Range
Min: 1.02   Max: 10.34
Current: 2.58

1.02
10.34
PFCF 22.38
BSX's PFCF is ranked higher than
72% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 27.48 vs. BSX: 22.38 )
BSX' s 10-Year PFCF Range
Min: 7.25   Max: 192.5
Current: 22.38

7.25
192.5
EV-to-EBIT 185.70
BSX's EV-to-EBIT is ranked lower than
73% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 20.80 vs. BSX: 185.70 )
BSX' s 10-Year EV-to-EBIT Range
Min: 11.1   Max: 186.8
Current: 185.7

11.1
186.8

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.58
BSX's Price/DCF (Projected) is ranked higher than
69% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. BSX: 1.58 )
BSX' s 10-Year Price/DCF (Projected) Range
Min: 0.5   Max: 4.4
Current: 1.58

0.5
4.4
Price/Median PS Value 1.16
BSX's Price/Median PS Value is ranked higher than
58% of the 334 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. BSX: 1.16 )
BSX' s 10-Year Price/Median PS Value Range
Min: 0.48   Max: 4
Current: 1.16

0.48
4
Earnings Yield (Greenblatt) 0.50
BSX's Earnings Yield (Greenblatt) is ranked lower than
64% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: 4.50 vs. BSX: 0.50 )
BSX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 9
Current: 0.5

0.5
9
Forward Rate of Return (Yacktman) 2.58
BSX's Forward Rate of Return (Yacktman) is ranked higher than
80% of the 261 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. BSX: 2.58 )
BSX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.7   Max: 62.6
Current: 2.58

1.7
62.6

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:BSX.Germany
Boston Scientific, Inc., is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's products were offered for sale by seven core businesses - Interventional Cardiology, CRM, Endoscopy, Peripheral Interventions, Urology/Women's Health, Neuromodulation, and Electrophysiology. The Company derives 33 percent of its sales from its Interventional Cardiology business, 27 percent of its sales from its CRM business, 16 percent of its sales from its Endoscopy business, 10 percent of its sales from its Peripheral Interventions business, six percent of its sales from its Urology/Women's Health business, four percent of its sales from its Neuromodulation business, and two percent of its sales from its Electrophysiology business. It develops, manufactures and markets a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, including: Implantable cardiac defibrillator systems used to detect and treat abnormally fast heart rhythms that could result in sudden cardiac death, including implantable cardiac resynchronization therapy defibrillator systems used to treat heart failure; and Implantable pacemaker systems used to manage slow or irregular heart rhythms, including implantable cardiac resynchronization therapy pacemaker systems used to treat heart failure. Within the Company's Electrophysiology business, it offers medical devices for the diagnosis and treatment of cardiac arrhythmias. Included in its product offerings are RF generators, intracardiac ultrasound and steerable ablation catheters, and diagnostic catheters. The Company's main competitors include Abbott Laboratories; Medtronic, Inc.; St. Jude Medical, Inc.; and Johnson & Johnson as well as a wide range of medical device companies that sell a single or limited number of competitive products or participate in only a specific market segment. It also faces competition from non-medical device companies, such as pharmaceutical companies, which may offer alternative therapies for disease states intended to be treated using its products. The medical devices that the Company manufactures and markets are subject to regulation by numerous regulatory bodies, including the FDA and comparable international regulatory agencies.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide